Nevertheless, IDH-mutant WHO grade III astrocytomas show a much more favorable profile than their IDH-wildtype counterparts in terms of prognosis [58] and feasibility of gross total resection [59]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).